Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis
Background: The androgen receptor pathway inhibitors (ARPI), abiraterone acetate and enzalutamide, are commonly used in first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, early resistance to ARPI treatment occurs frequently. Traditionally, the res...
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
SAGE Publishing
2024-12-01
|
| 叢編: | Therapeutic Advances in Medical Oncology |
| 在線閱讀: | https://doi.org/10.1177/17588359241305084 |